Cediranib (AZD2171): ATP-Competitive VEGFR Tyrosine Kinase Inhibitor for Angiogenesis and Cancer Research

Executive Summary: Cediranib (AZD2171) is a highly potent, orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) with sub-nanomolar IC50 for VEGFR-2, making it a gold standard for angiogenesis inhibition in cancer research (Schwartz 2022). It exerts its effects by competitively binding the ATP site of VEGFR tyrosine kinases, thereby blocking VEGF-induced phosphorylation of downstream signaling proteins such as Akt (Ser473) (APExBIO). Cediranib also inhibits related tyrosine kinases, including c-Kit and PDGFRs, with variable potency, broadening its research utility. The compound is supplied as a solid under SKU A1882 by APExBIO, with optimal solubility in DMSO and recommended storage at -20°C. Cediranib is fundamental for in vitro modeling of angiogenesis and signal transduction in cancer biology (internal reference).

Biological Rationale

Angiogenesis is essential for tumor growth and metastasis, primarily mediated by signaling through VEGFRs. VEGF-driven phosphorylation cascades activate pathways that promote endothelial cell proliferation, migration, and survival. Aberrant VEGFR signaling correlates with increased tumor vascularization and poor prognosis in multiple cancers (Schwartz 2022). Inhibiting VEGFR activity is a validated strategy for impeding tumor angiogenesis. Cediranib (AZD2171) selectively targets VEGFR family kinases, providing a molecular tool for dissecting the angiogenic switch and its downstream consequences in preclinical and translational research.

Mechanism of Action of Cediranib (AZD2171)

Cediranib is an ATP-competitive, orally bioavailable small molecule inhibitor. It targets the ATP-binding site of VEGFR-1 (Flt-1), VEGFR-2 (KDR), and VEGFR-3 (Flt-4). The compound demonstrates an IC50 of < 1 nM for VEGFR-2, indicating exceptional potency in blocking receptor activation (APExBIO). Cediranib’s chemical structure—4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline—enables high-affinity, selective binding to the VEGFR kinase domain. Inhibition of VEGFR tyrosine kinase activity prevents VEGF-induced phosphorylation of intracellular signaling proteins such as Akt (Ser473), thereby disrupting the PI3K/Akt/mTOR pathway and impeding angiogenesis and tumor proliferation (Schwartz 2022). Cediranib also inhibits c-Kit, PDGFR-β, PDGFR-α, CSF-1R, and Flt-3, with IC50 values ranging from 0.002 to >1 μM, reflecting a broader but less potent kinase inhibition profile outside VEGFRs.

Evidence & Benchmarks

• Cediranib inhibits VEGFR-2 kinase activity with an IC50 of < 1 nM in cell-free kinase assays (APExBIO).
• In vitro, Cediranib suppresses VEGF-induced Akt (Ser473) phosphorylation, blocking downstream PI3K/Akt/mTOR signaling in endothelial cells (Schwartz 2022).
• It shows variable inhibition of c-Kit, PDGFR-β, and PDGFR-α, with IC50 values spanning 0.002 μM to >1 μM, depending on kinase and assay context (APExBIO).
• In cell-based angiogenesis models, Cediranib decreases endothelial proliferation and tube formation at nanomolar concentrations (Schwartz 2022).
• Long-term storage of Cediranib solutions is not recommended; compound stability is maintained with fresh DMSO preparation and -20°C storage (APExBIO).

For a comprehensive overview of Cediranib’s sub-nanomolar inhibition profile and multi-kinase specificity, see "Cediranib (AZD2171): Potent ATP-Competitive VEGFR Tyrosin...". This article extends earlier summaries by providing direct linkage between in vitro kinase inhibition and functional angiogenesis assays.

Applications, Limits & Misconceptions

Cediranib is widely adopted for:

• Dissecting VEGFR-dependent angiogenesis in tumor models.
• Evaluating PI3K/Akt/mTOR pathway modulation downstream of VEGFR blockade.
• Screening anti-angiogenic strategies in preclinical cancer studies.
• Supporting systems-level modeling of tumor microenvironment signaling (contrast with systems-level insights; this article offers granular molecular inhibition benchmarks and workflow-specific recommendations).

Common Pitfalls or Misconceptions

• Water/Ethanol Solubility: Cediranib is insoluble in water and ethanol; DMSO is required for stock solution preparation.
• Long-Term Storage: Cediranib solutions degrade over time; prepare fresh aliquots for each experiment.
• Non-VEGFR Targets: While Cediranib inhibits some PDGFR and c-Kit kinases, its potency is substantially lower than for VEGFR-2.
• Cell Type Specificity: Efficacy varies by cellular context; not all endothelial or tumor cells respond identically to VEGFR inhibition.
• Clinical vs. Research Use: Cediranib (A1882) is designed for research applications; its clinical use is governed by different regulatory frameworks.

For advanced experimental approaches, see "Cediranib (AZD2171): Advanced In Vitro Modeling for VEGFR...". This article clarifies how to leverage Cediranib’s specificity for next-generation pathway modeling, whereas the present article emphasizes experimental controls and quantitative benchmarks.

Workflow Integration & Parameters

Cediranib (AZD2171) is supplied as a solid (molecular weight: 450.51; formula: C25H27FN4O3) and should be dissolved in DMSO at concentrations ≥22.52 mg/mL. For optimal results, store at -20°C and use freshly prepared solutions. Standard in vitro workflows include kinase assays, cell-based angiogenesis models, and signal transduction analyses. Concentration ranges for effective VEGFR inhibition typically span 0.1–100 nM, but should be empirically determined for each system. APExBIO recommends immediate use after solution preparation to avoid degradation (Cediranib (AZD2171) product page).

For guidance on integrating Cediranib into systems-biology protocols, see "Cediranib (AZD2171): Systems-Level Insights into VEGFR In...". While that resource explores network-wide implications, the current article provides actionable details for bench-level optimization and experimental reproducibility.

Conclusion & Outlook

Cediranib (AZD2171) remains a cornerstone reagent for investigating VEGFR signaling, angiogenesis, and cancer progression in vitro. Its high selectivity and potency, as supplied by APExBIO under SKU A1882, enable robust and reproducible experimental workflows in cancer research. As in vitro models evolve, Cediranib’s ATP-competitive inhibition profile and multi-kinase activity continue to facilitate mechanistic insight and translational advances (Schwartz 2022). For further product specifications or ordering, refer to the Cediranib (AZD2171) product page.